SCHEDULE 13G: Telix Pharmaceuticals: Dr. Christian Behrenbruch and Family Trust Disclose 6.97% Passive Stake
Beneficial Ownership Disclosure
Dr. Christian Behrenbruch, along with Elk River Holdings Pty Ltd, has disclosed a combined beneficial ownership of 6.97% of Telix Pharmaceuticals Ltd's ordinary shares, primarily held through a family trust, as a passive investment.
Summary
- Dr. Christian Behrenbruch and Elk River Holdings Pty Ltd (the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Telix Pharmaceuticals Ltd.
- As of November 12, 2024, Dr. Christian Behrenbruch beneficially owns an aggregate of 23,329,006 ordinary shares, representing 6.97% of the class.
- This ownership includes 654,006 shares under his sole voting and dispositive power, comprising 153,298 ordinary shares, 400,000 American Depositary Shares (ADSs), and 100,708 ordinary shares issuable from options exercisable within 60 days of September 30, 2024.
- Dr. Behrenbruch also shares voting and dispositive power over 22,675,000 ordinary shares held by Elk River Holdings Pty Ltd as Trustee for the Behrenbruch Family Trust, where he is the sole director and shareholder.
- Elk River Holdings Pty Ltd separately reports beneficial ownership of 22,675,000 ordinary shares, representing 6.78% of the class, all under shared voting and dispositive power.
- The beneficial ownership percentages are based on 334,683,357 ordinary shares outstanding as of September 30, 2024, as reported in Telix's Form 20-F filed on October 17, 2024.
- The filing indicates a passive investment purpose under Rule 13d-1(c).
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's operational performance or financial health. It is a routine regulatory filing.
Positives
- The disclosure confirms a significant ownership stake by a key individual (Dr. Christian Behrenbruch) and his family trust, which can signal alignment of interests with long-term company performance.
Industry Context
This filing is a routine disclosure of significant beneficial ownership and does not provide insights into broader industry trends or competitive dynamics. It primarily concerns the ownership structure of Telix Pharmaceuticals Ltd.
Related Party Transactions
- The beneficial ownership includes 22,675,000 ordinary shares held by Elk River Holdings Pty Ltd as Trustee for the Behrenbruch Family Trust, where Dr. Christian Behrenbruch is the sole director and shareholder, indicating a related party holding structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by a key insider and associated entities, which can influence perceptions of corporate control and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Date as of which 334,683,357 ordinary shares were outstanding, as reported in the Issuer's Form 20-F. |
| 2024-10-17 | Date Telix Pharmaceuticals Ltd filed its Form 20-F with the SEC, reporting shares outstanding. |
| 2024-11-12 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
Telix Pharmaceuticals, TLX, Christian Behrenbruch, Elk River Holdings, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Passive Investment, SEC Filing, Shareholding Disclosure, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.